| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2a8168e47a50e0d4f4b728bebd0c96a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74d47c8ac61b60a986aff3069a2dc30c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_124cac2c3d7b18131136364d9f762bf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7aca1fd968d84e1c6780c43fc854b2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055 |
| filingDate |
2006-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4a47a1633c52fea387110eb6de37441
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_367f4f614d2519e940c191d4ed2d8dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12e4d2b4d70525cd204c7cca39f6e9b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ee43c2ac9c0ce3aedaea1f9a1b472b3 |
| publicationDate |
2008-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008213190-A1 |
| titleOfInvention |
Selective Alfavbetas Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications |
| abstract |
The present invention is related to new peptide antagonists of α v β 3 receptor, designed on the basis of the crystal structure of integrin α v β 3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the α v β 3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for α v β 3 -targeted therapy and imaging. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9775803-B2 |
| priorityDate |
2005-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |